AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39622578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMR)
Number of subjects: 49
Study 39622823 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive rosuvastatin
Number of subjects: 24
Study 39622823 — intervention group
Group type: COMPARATOR
Intervention: Standard tuberculosis treatment
Number of subjects: 24
Study 39623189 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB/targeted axillary dissection
Number of subjects: 2407
Study 39623189 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 2407
Study 39623189 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pCR in the breast
Number of subjects: 2407
Study 39623189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonluminal pathology
Number of subjects: 2407
Study 39623189 — intervention group
Group type: EXPERIMENTAL
Intervention: Age younger than 45 years
Number of subjects: 2407
Study 39623189 — intervention group
Group type: EXPERIMENTAL
Intervention: cT3-T4, no breast pCR (non-pCR), ypN(+), nonluminal pathology
Number of subjects: 2407
Study 39623189 — intervention group
Group type: EXPERIMENTAL
Intervention: ypN2 or ypN3 disease
Number of subjects: 2407
Study 39623365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan (200 mg for the first 5 days, then 100 mg for the subsequent 35 days, twice daily)
Number of subjects: 50
Study 39623365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 39623365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 50
Study 39623426 — intervention group
Group type: EXPERIMENTAL
Intervention: ADSC spray therapy
Number of subjects: 7
Study 39623426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 39623502 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release buprenorphine (XR-BUP) - single injection of a 28-day formulation within 72-hours of anticipated hospital discharge.
Number of subjects: 342
Study 39623502 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) - may consist of any MOUD other than XR-BUP.
Number of subjects: 342
Study 39623502 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release buprenorphine (XR-BUP)
Number of subjects: 342
Study 39623529 — intervention group
Group type: COMPARATOR
Intervention: Non-AE group (patients without adverse events)
Number of subjects: 32
Study 39623529 — intervention group
Group type: EXPERIMENTAL
Intervention: AE group (patients with adverse events)
Number of subjects: 32
Study 39623757 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced systemic therapy (AST) including dupilumab and upadacitinib
Number of subjects: 436
Study 39623757 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced systemic therapy (AST)
Number of subjects: 436
Study 39623757 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 436
Study 39624149 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention with cognitive and behavioral therapeutic elements
Number of subjects: 0
Study 39624149 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39624175 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOT1 overexpression
Number of subjects: 0
Study 39624175 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOT1 silencing
Number of subjects: 0
Study 39624175 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 39624188 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic pneumatic ventilation
Number of subjects: 514
Study 39624188 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve-mask ventilation
Number of subjects: 514
Study 39624459 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine treatment (30-day subcutaneous administration)
Number of subjects: 13
Study 39624459 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 13
Study 39624459 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine treatment
Number of subjects: 13
Study 39624518 — intervention group
Group type: EXPERIMENTAL
Intervention: simoctocog alfa (Nuwiq)
Number of subjects: 28
Study 39624736 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical OA 0.5%
Number of subjects: 48
Study 39624736 — intervention group
Group type: COMPARATOR
Intervention: Topical retinol 0.5%
Number of subjects: 48
Study 39624747 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave treatment (Swift device)
Number of subjects: 0
Study 39624833 — intervention group
Group type: EXPERIMENTAL
Intervention: HAIC sequential TAE combined with tislelizumab and surufatinib
Number of subjects: 0
Study 39624892 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific out-of-pocket (OOP) cost estimates provided during encounters
Number of subjects: 247
Study 39624892 — intervention group
Group type: COMPARATOR
Intervention: Standard care without patient-specific OOP cost estimates
Number of subjects: 247
Study 39624908 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD (S-ICD)
Number of subjects: 849
Study 39624908 — intervention group
Group type: COMPARATOR
Intervention: Transvenous ICD (TV-ICD)
Number of subjects: 849
Study 39624908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both S-ICD and TV-ICD
Number of subjects: 849
Study 39624908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention after first IAS
Number of subjects: 849
Study 39624922 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HBcrAg levels at end of treatment (EOT)
Number of subjects: 78
Study 39624922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower anti-HBc levels at EOT
Number of subjects: 78
Study 39624922 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HBcrAg/anti-HBc ratio at EOT
Number of subjects: 78
Study 39624922 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HBcrAg levels at follow-up week 6 (FUW6)
Number of subjects: 78
Study 39624922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower anti-HBc levels at FUW6
Number of subjects: 78
Study 39624922 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HBcrAg/anti-HBc ratio at FUW6
Number of subjects: 78
Study 39624936 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Laboratory (ECL) assessment
Number of subjects: 1118
Study 39624936 — intervention group
Group type: COMPARATOR
Intervention: Center-reported echocardiographic assessment
Number of subjects: 1118
Study 39625044 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lymphocyte subpopulations characterized by flow cytometry
Number of subjects: 167
Study 39625044 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two consecutive markers
Number of subjects: 167
Study 39625230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 4 weeks (Q4W) with topical corticosteroids (TCS)
Number of subjects: 286
Study 39625230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks (Q2W) with topical corticosteroids (TCS)
Number of subjects: 286
Study 39625230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 39625244 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg daily starting post-operative day 2 until 1 day after chest tube removal
Number of subjects: 9
Study 39625244 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (previously published, n = 25)
Number of subjects: 9
Study 39625263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) + Treatment as usual (TAU)
Number of subjects: 144
Study 39625263 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 144
Study 39625429 — intervention group
Group type: EXPERIMENTAL
Intervention: Exome+ assay (whole exome sequencing plus ∼300,000 single nucleotide polymorphisms)
Number of subjects: 98222
Study 39625429 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication of positive results by genetic counselors
Number of subjects: 98222
Study 39625429 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to Exome+ assays for research
Number of subjects: 98222
Study 39625478 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib (25 mg orally twice daily) with docetaxel (75 mg/m2 IV every 21-days)
Number of subjects: 26
Study 39625478 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib with docetaxel
Number of subjects: 26
Study 39625569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib with neoadjuvant paclitaxel
Number of subjects: 9
Study 39625569 — intervention group
Group type: COMPARATOR
Intervention: Standard neoadjuvant therapy with paclitaxel and adriamycin/cyclophosphamide
Number of subjects: 9
Study 39625640 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage (10 minutes total, applied before each brachytherapy session for 1 week)
Number of subjects: 24
Study 39625640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 39625696 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous 15 mg/kg amikacin dose
Number of subjects: 0
Study 39625696 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat 1500-mg dose
Number of subjects: 0
Study 39625696 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat 3500-mg dose
Number of subjects: 0
Study 39625696 — intervention group
Group type: COMPARATOR
Intervention: 15 mg/kg dosing
Number of subjects: 0
Study 39625722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib, 150 mg orally twice daily for 14 days
Number of subjects: 400
Study 39625722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 39625722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 400
Study 39625741 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic eHealth intervention
Number of subjects: 280
Study 39625741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study 39626074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 62
Study 39626074 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol transdermal patches
Number of subjects: 62
Study 39626074 — intervention group
Group type: COMPARATOR
Intervention: Placebo for sertraline
Number of subjects: 62
Study 39626074 — intervention group
Group type: COMPARATOR
Intervention: Placebo for estradiol
Number of subjects: 62
Study 39626074 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 62
Study 39626127 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ocrelizumab 600 mg every 24 weeks
Number of subjects: 678
Study 39626160 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg orally once daily on a 28-day cycle
Number of subjects: 37
Study 39626160 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 37
Study 39626227 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Symptom Management System (ASyMS)
Number of subjects: 29
Study 39626287 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 49
Study 39626287 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 49
Study 39626300 — intervention group
Group type: EXPERIMENTAL
Intervention: Inaticabtagene Autoleucel (Inati-cel) infusion
Number of subjects: 48
Study 39626332 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT with CF)
Number of subjects: 124
Study 39626332 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 124
Study 39626332 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT with CF
Number of subjects: 124
Study 39626332 — intervention group
Group type: COMPARATOR
Intervention: SP
Number of subjects: 124
Study 39626345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipocyte size measurement in various fat depots (subcutaneous, visceral, retroperitoneal, mammary)
Number of subjects: 22
Study 39626345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipocyte size measurement in mammary fat at autopsy
Number of subjects: 22
Study 39626345 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of adipocyte size with BMI at death
Number of subjects: 22
Study 39626345 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of tumor infiltration in visceral fat
Number of subjects: 22
Study 39626378 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ-hTreg (VT301) low dose
Number of subjects: 6
Study 39626378 — intervention group
Group type: EXPERIMENTAL
Intervention: Aβ-hTreg (VT301) high dose
Number of subjects: 6
Study 39626378 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study 39626407 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad test battery including Short Physical Performance Battery, Single Leg Stance, Chair Stand Test, 10mWT, 2 Minute Walk Tests, limb circumference, dynamometry, Clinical Frailty Scale, SHARE-Frailty Instrument, Numerical Pain Rating Scale, Short Form-12
Number of subjects: 74
Study 39626445 — intervention group
Group type: EXPERIMENTAL
Intervention: Reirradiation of diffuse midline glioma patients
Number of subjects: 0
Study 39626671 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural stem cell transplantation (NSI-566)
Number of subjects: 4
Study 39626674 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 345
Study 39626674 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis (CH)
Number of subjects: 345
Study 39626674 — intervention group
Group type: COMPARATOR
Intervention: Control group (without HIV)
Number of subjects: 345
Study 39627012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnut flour added to gluten-free corn flour in different amounts
Number of subjects: 0
Study 39627012 — intervention group
Group type: COMPARATOR
Intervention: Control group (gluten-free corn flour without hazelnut flour)
Number of subjects: 0
Study 39627123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) interventions selected by an algorithm
Number of subjects: 12
Study 39627123 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pain disability measures (Pain Disability Index and adapted Quebec Back Pain Disability Scale)
Number of subjects: 12
Study 39627133 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor (ICI) rechallenge
Number of subjects: 1016
Study 39627139 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus platinum and gemcitabine (PG)
Number of subjects: 26
Study 39627217 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg daily for 12 months
Number of subjects: 35
Study 39627222 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole regimens and combinations
Number of subjects: 0
Study 39627222 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiCruzi serological method
Number of subjects: 0
Study 39627222 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR data
Number of subjects: 0
Study 39627496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 0
Study 39627496 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Pain Coping Skills Training (PCST)
Number of subjects: 0
Study 39627624 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone (8 mg, 2 mL)
Number of subjects: 25
Study 39627624 — intervention group
Group type: COMPARATOR
Intervention: Submucosal normal saline
Number of subjects: 25
Study 39627701 — intervention group
Group type: EXPERIMENTAL
Intervention: RSM01 (300 mg IV, 300 mg IM, 1000 mg IV, 3000 mg IV, 600 mg IM)
Number of subjects: 56
Study 39627701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 39627771 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy food nudges (combination of placement and property nudges)
Number of subjects: 638
Study 39627771 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 638
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Return-to-work expectancy
Number of subjects: 509
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 509
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 509
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 509
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived health
Number of subjects: 509
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep quality
Number of subjects: 509
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Work satisfaction
Number of subjects: 509
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 509
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting disorder expectation
Number of subjects: 509
Study 39627785 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare utilization and productivity loss
Number of subjects: 509
Study 39627786 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment for 2 weeks
Number of subjects: 46
Study 39627786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 39627789 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted STAIR-NT intervention (massed treatment model with four 60-min sessions of skill building and two weeks of four 60-min sessions of narrative therapy)
Number of subjects: 80
Study 39627789 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 80
Study 39627794 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (n=112)
Number of subjects: 219
Study 39627794 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=107)
Number of subjects: 219
Study 39627831 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulse electromagnetic field therapy and standard exercise training
Number of subjects: 48
Study 39627831 — intervention group
Group type: COMPARATOR
Intervention: Sham pulse electromagnetic field therapy and standard exercise training
Number of subjects: 48
Study 39627888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bactogram method applied to suction blister wounds
Number of subjects: 24
Study 39627888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bactogram method with chromogenic agar
Number of subjects: 24
Study 39627888 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantification methods based on visual scoring and image analysis
Number of subjects: 24
Study 39628466 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich supplement (specific dosage and duration not mentioned)
Number of subjects: 0
Study 39628618 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat (100 mg twice daily to 200 mg three times daily)
Number of subjects: 17
Study 39628893 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery (ES) for hematoma evacuation within 24 hours after bleeding onset.
Number of subjects: 10
Study 39628893 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery (ES) for hematoma evacuation.
Number of subjects: 10
Study 39629185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) and positive psychology therapy (PPT)
Number of subjects: 0
Study 39629185 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39629586 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 39
Study 39629675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic assessment using the Glaspey Dynamic Assessment of Phonology's scoring system
Number of subjects: 2
Study 39629675 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cycles approach administered by an SLT and a student clinician
Number of subjects: 2
Study 39629836 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2038 subcutaneous (SC) buprenorphine (BPN) extended-release injections
Number of subjects: 428
Study 39629836 — intervention group
Group type: COMPARATOR
Intervention: Daily sublingual (SL) BPN/naloxone (BPN/NX) tablets
Number of subjects: 428
Study 39629943 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-delivered, motivational interviewing-based parental support program (counseling every other week for 1 year)
Number of subjects: 151
Study 39629943 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-delivered, motivational interviewing-based parental support program
Number of subjects: 151
Study 39629943 — intervention group
Group type: COMPARATOR
Intervention: Standard advice on toothbrushing and sugar reduction (control group)
Number of subjects: 151
Study 39630028 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) treatment
Number of subjects: 4174
Study 39630028 — intervention group
Group type: COMPARATOR
Intervention: Non-OCA treatment (control)
Number of subjects: 4174
Study 39630057 — intervention group
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa at 1.5 mg/kg every 4 weeks (Q4W)
Number of subjects: 106
Study 39630057 — intervention group
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa therapy
Number of subjects: 106
Study 39630067 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-lactam antibiotics (11 different types)
Number of subjects: 57
Study 39630083 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine and Samidorphan
Number of subjects: 0
Study 39630397 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide administration
Number of subjects: 27
Study 39630545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory (PedsQL) scale
Number of subjects: 135
Study 39630545 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Status Scale (FSS)
Number of subjects: 135
Study 39630545 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress syndrome (PTSS) assessment
Number of subjects: 135
Study 39630545 — intervention group
Group type: EXPERIMENTAL
Intervention: Trajectory groups identification
Number of subjects: 135
Study 39630588 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel foot (Ottobock Evanto)
Number of subjects: 20
Study 39630588 — intervention group
Group type: COMPARATOR
Intervention: Everyday foot
Number of subjects: 20